Skip to main content

Table 2 Frequency of adverse events among the three groups.

From: Safety and tolerability of nevirapine-based antiretroviral therapy in HIV-infected patients receiving fluconazole for cryptococcal prophylaxis: a retrospective cohort study

Adverse events Not receiving fluconazole Receiving fluconazole Pvalue
  (n = 225) 400 mg/week (n = 392) 200 mg/day (n = 69)  
Clinical hepatitis 2/225 (0.9%) 4/392 (1.0%) 0/69 (0%) 0.705
Elevated AST > 3 times from baseline 3/104 (2.9%) 5/188 (2.7%) 3/36 (8.3%) 0.192
Elevated ALT > 3 times from baseline 6/71 (8.5%) 7/95 (7.4%) 2/22 (9.1%) 0.938
Skin Rash 23/225 (10.2%) 27/392 (6.9%) 0/69 (0%) 0.016